Ionis Regains Rights To Thrombosis Candidate From Bayer

  • Ionis Pharmaceuticals Inc IONS announced results from the Phase 2b RE-THINC ESRD study of fesomersen to reduce the production of Factor XI (FXI) for the prevention of thrombosis.
  • Ionis to regain rights to fesomersen from Bayer AG BAYRY
  • The RE-THINC ESRD study evaluated fesomersen in patients with end-stage renal disease (ESRD) on hemodialysis.
  • In the study, fesomersen achieved its primary endpoint, demonstrating no increase in the incidence of the composite of major bleeding and clinically relevant non-major (CRNM) bleeding with 24 weeks of treatment. 
  • Related: There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%.
  • Fesomersen also achieved dose-dependent and sustained median reductions in steady-state FXI levels of 53.1%, 72.2%, and 86.6% in the 40 mg, 80 mg, and 120 mg doses of fesomersen, respectively, administered once every four weeks. 
  • Incidences of dialysis circuit clotting and AV-access thrombosis diminished significantly with decreasing FXI levels, both of which were exploratory efficacy endpoints. 
  • Fesomersen showed favorable safety and tolerability.
  • Price Action: IONS shares are down 2.46% at $43.40 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!